Italia markets close in 2 hours 8 minutes

FTSE MIB
34.928,45
-470,37(-1,33%)
Dow Jones
40.003,59
+134,19(+0,34%)
Nasdaq
16.685,97
-12,33(-0,07%)
Nikkei 225
39.069,68
+282,30(+0,73%)
Petrolio
79,48
-0,58(-0,72%)
Bitcoin EUR
61.738,75
+156,78(+0,25%)

NVCR Jun 2024 10.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

8,13

0,00

(0,00%)

In data: 09:30AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in